Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results

Personalis (NASDAQ:PSNL) released its quarterly earnings data on Wednesday. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06), FiscalAI reports. The firm had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $21.54 million. Personalis had a negative return on equity of 47.66% and a negative net margin of 147.74%.

Personalis Stock Up 0.5%

Shares of PSNL traded up $0.09 during mid-day trading on Friday, hitting $15.63. 1,180,140 shares of the company traded hands, compared to its average volume of 2,608,563. The company has a market capitalization of $1.64 billion, a PE ratio of -13.37 and a beta of 2.40. Personalis has a 1-year low of $4.95 and a 1-year high of $18.89. The business has a 50 day moving average of $16.20 and a 200 day moving average of $11.44.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PSNL shares. Zacks Research raised Personalis from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. TD Cowen restated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Thursday, October 15th. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Finally, Craig Hallum downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price on the stock. in a research report on Monday, August 24th. Two research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Personalis currently has a consensus rating of “Hold” and a consensus target price of $15.29.

Insider Transactions at Personalis

In other Personalis news, SVP Stephen Moore sold 2,068 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $33,542.96. Following the completion of the transaction, the senior vice president directly owned 90,257 shares of the company’s stock, valued at approximately $1,463,968.54. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Richard Chen sold 3,998 shares of the business’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $64,847.56. Following the transaction, the chief marketing officer owned 169,882 shares of the company’s stock, valued at $2,755,486.04. This represents a 2.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 16,456 shares of company stock valued at $266,916 in the last quarter. Insiders own 4.20% of the company’s stock.

Personalis Company Profile

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.